{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-10-02",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "70165-025",
      "generic_name": "Amphetamine",
      "labeler_name": "Neos Therapeutics Brands, LLC",
      "dea_schedule": "CII",
      "brand_name": "Adzenys XR-ODT",
      "active_ingredients": [
        {
          "name": "AMPHETAMINE",
          "strength": "15.7 mg/1"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "70165-025-30",
          "description": "30 BLISTER PACK in 1 CARTON (70165-025-30)  / 6 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK",
          "marketing_start_date": "20160216",
          "sample": false
        },
        {
          "package_ndc": "70165-025-31",
          "description": "30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70165-025-31)",
          "marketing_start_date": "20261001",
          "sample": false
        }
      ],
      "listing_expiration_date": "20271231",
      "openfda": {},
      "marketing_category": "NDA",
      "dosage_form": "TABLET, ORALLY DISINTEGRATING",
      "spl_id": "51b6449e-77c9-3dac-e063-6294a90aaeb6",
      "product_type": "HUMAN PRESCRIPTION DRUG",
      "route": [
        "ORAL"
      ],
      "marketing_start_date": "20160216",
      "product_id": "70165-025_51b6449e-77c9-3dac-e063-6294a90aaeb6",
      "application_number": "NDA204326",
      "brand_name_base": "Adzenys XR-ODT",
      "pharm_class": [
        "Central Nervous System Stimulant [EPC]",
        "Central Nervous System Stimulation [PE]"
      ]
    }
  ]
}